

Martin Reincke

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7093759/publications.pdf>

Version: 2024-02-01

169
papers

11,816
citations

30047

54
h-index

30894

102
g-index

172
all docs

172
docs citations

172
times ranked

6244
citing authors

#	ARTICLE	IF	CITATIONS
1	Drug-resistant hypertension in primary aldosteronism patients undergoing adrenal vein sampling: the AVIS-2-RH study. <i>European Journal of Preventive Cardiology</i> , 2022, 29, e85-e93.	0.8	19
2	Endocrine risk factors for COVID-19: Endogenous and exogenous glucocorticoid excess. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2022, 23, 233-250.	2.6	13
3	Plasma Steroid Profiling in Patients With Adrenal Incidentaloma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e1181-e1192.	1.8	19
4	Pathophysiology and histopathology of primary aldosteronism. <i>Trends in Endocrinology and Metabolism</i> , 2022, 33, 36-49.	3.1	14
5	Medullary thyroid cancer with ectopic Cushing's syndrome: A multicentre case series. <i>Clinical Endocrinology</i> , 2022, 96, 847-856.	1.2	7
6	Feasibility of Imaging-Guided Adrenalectomy in Young Patients With Primary Aldosteronism. <i>Hypertension</i> , 2022, 79, 187-195.	1.3	13
7	Improving Diagnostic Efficiency with Frequency Double-Trees and Frequency Nets in Bayesian Reasoning. <i>MDM Policy and Practice</i> , 2022, 7, 238146832210866.	0.5	2
8	Personalized drug testing in human pheochromocytoma/paraganglioma primary cultures. <i>Endocrine-Related Cancer</i> , 2022, 29, 285-306.	1.6	12
9	Long-term morbidity and mortality in patients with Cushing's syndrome. <i>Journal of Neuroendocrinology</i> , 2022, 34, e13113.	1.2	31
10	Clinical Biology of the Pituitary Adenoma. <i>Endocrine Reviews</i> , 2022, 43, 1003-1037.	8.9	81
11	True unilateral primary aldosteronism exists, and unilateral adrenalectomy saves lives.. <i>European Journal of Endocrinology</i> , 2022, , .	1.9	2
12	The Saline Infusion Test for Primary Aldosteronism: Implications of Immunoassay Inaccuracy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e2027-e2036.	1.8	27
13	Identification of predictive criteria for pathogenic variants of primary bilateral macronodular adrenal hyperplasia (PBMAH) gene <i>ARMC5</i> in 352 unselected patients. <i>European Journal of Endocrinology</i> , 2022, 187, 123-134.	1.9	18
14	The NETting of pituitary adenoma: a gland illusion. <i>Pituitary</i> , 2022, 25, 349-351.	1.6	12
15	Improved pasireotide response in USP8 mutant corticotroph tumours in vitro. <i>Endocrine-Related Cancer</i> , 2022, 29, 503-511.	1.6	11
16	Whom Should We Screen for Cushing Syndrome? The Endocrine Society Practice Guideline Recommendations 2008 Revisited. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e3723-e3730.	1.8	14
17	The metabolic phenotype of patients with primary aldosteronism: impact of subtype and sex – a multicenter-study of 3566 Caucasian and Asian subjects. <i>European Journal of Endocrinology</i> , 2022, 187, 361-372.	1.9	9
18	Histopathology and Genetic Causes of Primary Aldosteronism in Young Adults. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 2473-2482.	1.8	4

#	ARTICLE	IF	CITATIONS
19	International Histopathology Consensus for Unilateral Primary Aldosteronism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 42-54.	1.8	127
20	Adrenal Venous Samplingâ€“Guided Adrenalectomy Rates in Primary Aldosteronism: Results of an International Cohort (AVSTAT). <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e1400-e1407.	1.8	25
21	Volumetric Modeling of Adrenal Gland Size in Primary Bilateral Macronodular Adrenocortical Hyperplasia. <i>Journal of the Endocrine Society</i> , 2021, 5, bvaa162.	0.1	7
22	Single-cell molecular profiling of all three components of the HPA axis reveals adrenal ABCB1 as a regulator of stress adaptation. <i>Science Advances</i> , 2021, 7, .	4.7	42
23	Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time?. <i>Journal of the Endocrine Society</i> , 2021, 5, bvaa205.	0.1	31
24	Circulating microRNA Expression in Cushingâ€™s Syndrome. <i>Frontiers in Endocrinology</i> , 2021, 12, 620012.	1.5	11
25	Genomics in Cushingâ€™s Disease: The Dawn of a New Era. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e2455-e2456.	1.8	7
26	Autonomous Cortisol Secretion Influences Psychopathological Symptoms in Patients With Primary Aldosteronism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e2423-e2433.	1.8	7
27	Perspectives of the European Society of Endocrinology (ESE) and the European Society of Paediatric Endocrinology (ESPE) on rare endocrine disease. <i>Endocrine</i> , 2021, 71, 539-541.	1.1	3
28	Approach to the Patient Treated with Steroidogenesis Inhibitors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 2114-2123.	1.8	39
29	Altered Taste Perception for Sodium Chloride in Patients With Primary Aldosteronism. <i>Hypertension</i> , 2021, 77, 1332-1340.	1.3	14
30	Characteristics of preoperative steroid profiles and glucose metabolism in patients with primary aldosteronism developing adrenal insufficiency after adrenalectomy. <i>Scientific Reports</i> , 2021, 11, 11181.	1.6	6
31	BEX1 Is Differentially Expressed in Aldosterone-Producing Adenomas and Protects Human Adrenocortical Cells From Ferroptosis. <i>Hypertension</i> , 2021, 77, 1647-1658.	1.3	8
32	Patients with low IGF-I after curative surgery for Cushingâ€™s syndrome have an adverse long-term outcome of hypercortisolism-induced myopathy. <i>European Journal of Endocrinology</i> , 2021, 184, 813-821.	1.9	13
33	The role of regulated necrosis in endocrine diseases. <i>Nature Reviews Endocrinology</i> , 2021, 17, 497-510.	4.3	35
34	Cushing Syndrome Associated Myopathy: It Is Time for a Change. <i>Endocrinology and Metabolism</i> , 2021, 36, 564-571.	1.3	16
35	Primary Aldosteronism: Metabolic Reprogramming and the Pathogenesis of Aldosterone-Producing Adenomas. <i>Cancers</i> , 2021, 13, 3716.	1.7	6
36	Identification of Surgically Curable Primary Aldosteronism by Imaging in a Large, Multiethnic International Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e4340-e4349.	1.8	18

#	ARTICLE	IF	CITATIONS
37	Single-Center Prospective Cohort Study on the Histopathology, Genotype, and Postsurgical Outcomes of Patients With Primary Aldosteronism. <i>Hypertension</i> , 2021, 78, 738-746.	1.3	35
38	Targeted Metabolomics as a Tool in Discriminating Endocrine From Primary Hypertension. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e1111-e1128.	1.8	19
39	IGF-I/IGFBP3/ALS Deficiency in Sarcopenia: Low GHBP Suggests GH Resistance in a Subgroup of Geriatric Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 1698-1707.	1.8	13
40	Development of a Prediction Score to Avoid Confirmatory Testing in Patients With Suspected Primary Aldosteronism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 1708-1716.	1.8	16
41	Consensus on diagnosis and management of Cushing's disease: a guideline update. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 847-875.	5.5	315
42	Metformin and Bone Metabolism in Endogenous Glucocorticoid Excess: An Exploratory Study. <i>Frontiers in Endocrinology</i> , 2021, 12, 765067.	1.5	5
43	Genomic epidemiology reveals multiple introductions of SARS-CoV-2 followed by community and nosocomial spread, Germany, February to May 2020. <i>Eurosurveillance</i> , 2021, 26, .	3.9	11
44	Diagnosis and treatment of primary aldosteronism. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 876-892.	5.5	106
45	Evidence for increased SARS-CoV-2 susceptibility and COVID-19 severity related to pre-existing immunity to seasonal coronaviruses. <i>Cell Reports</i> , 2021, 37, 110169.	2.9	34
46	Subtyping of Primary Aldosteronism in the AVIS-2 Study: Assessment of Selectivity and Lateralization. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 2042-2052.	1.8	65
47	Glucocorticoid Receptor Polymorphisms Influence Muscle Strength in Cushing's Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 305-313.	1.8	14
48	Patients With Primary Aldosteronism Respond to Unilateral Adrenalectomy With Long-Term Reduction in Salt Intake. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e484-e493.	1.8	12
49	Response to the Letter to the Editor: "Long-Term Outcome of Primary Bilateral Macronodular Adrenocortical Hyperplasia After Unilateral Adrenalectomy". <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e922-e923.	1.8	0
50	Response to Letter to the Editor: "Impaired Glucose Metabolism in Primary Aldosteronism Is Associated with Cortisol Cosecretion". <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e916-e917.	1.8	1
51	Time to Diagnosis in Cushing's Syndrome: A Meta-Analysis Based on 5367 Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e12-e22.	1.8	69
52	The Primary Aldosteronism Surgical Outcome Score for the Prediction of Clinical Outcomes After Adrenalectomy for Unilateral Primary Aldosteronism. <i>Annals of Surgery</i> , 2020, 272, 1125-1132.	2.1	66
53	Histological Characterization of Aldosterone-producing Adrenocortical Adenomas with Different Somatic Mutations. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e282-e289.	1.8	29
54	Use of Steroid Profiling Combined With Machine Learning for Identification and Subtype Classification in Primary Aldosteronism. <i>JAMA Network Open</i> , 2020, 3, e2016209.	2.8	53

#	ARTICLE	IF	CITATIONS
55	Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test validation study. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 773-781.	5.5	129
56	Recurrence after pituitary surgery in adult Cushing's disease: a systematic review on diagnosis and treatment. <i>Endocrine</i> , 2020, 70, 218-231.	1.1	40
57	The potential pathophysiological role of aldosterone and the mineralocorticoid receptor in anxiety and depression – Lessons from primary aldosteronism. <i>Journal of Psychiatric Research</i> , 2020, 130, 82-88.	1.5	20
58	Subtype diagnosis, treatment, complications and outcomes of primary aldosteronism and future direction of research: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension –. <i>Journal of Hypertension</i> , 2020, 38, 1929-1936.	0.3	74
59	Systemic Effects by Intrathecal Administration of Triamcinolone Acetonide in Patients With Multiple Sclerosis. <i>Frontiers in Endocrinology</i> , 2020, 11, 574.	1.5	4
60	Persisting Muscle Dysfunction in Cushing's Syndrome Despite Biochemical Remission. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e4490-e4498.	1.8	29
61	Nomogram-Based Preoperative Score for Predicting Clinical Outcome in Unilateral Primary Aldosteronism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e4382-e4392.	1.8	20
62	The Impact of Glucocorticoid Co-Secretion in Primary Aldosteronism on Thyroid Autoantibody Titers During the Course of Disease. <i>Hormone and Metabolic Research</i> , 2020, 52, 404-411.	0.7	6
63	Development and Validation of Prediction Models for Subtype Diagnosis of Patients With Primary Aldosteronism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e3706-e3717.	1.8	47
64	Spironolactone reduces biochemical markers of bone turnover in postmenopausal women with primary aldosteronism. <i>Endocrine</i> , 2020, 69, 625-633.	1.1	10
65	Glucocorticoid Excess in Patients with Pheochromocytoma Compared with Paraganglioma and Other Forms of Hypertension. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e3374-e3383.	1.8	17
66	Metformin: the white knight fighting corticosteroid side-effects. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 258-259.	5.5	2
67	Mass Spectrometry Imaging Establishes 2 Distinct Metabolic Phenotypes of Aldosterone-Producing Cell Clusters in Primary Aldosteronism. <i>Hypertension</i> , 2020, 75, 634-644.	1.3	33
68	What is the role of medical therapy in adrenal-dependent Cushing's syndrome?. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2020, 34, 101376.	2.2	7
69	Mass spectrometry reveals misdiagnosis of primary aldosteronism with scheduling for adrenalectomy due to immunoassay interference. <i>Clinica Chimica Acta</i> , 2020, 507, 98-103.	0.5	8
70	ENDOCRINOLOGY IN THE TIME OF COVID-19: Management of Cushing's syndrome. <i>European Journal of Endocrinology</i> , 2020, 183, G1-G7.	1.9	61
71	Mass spectrometry-based steroid profiling in primary bilateral macronodular adrenocortical hyperplasia. <i>Endocrine-Related Cancer</i> , 2020, 27, 403-413.	1.6	13
72	Prospective evaluation of aldosterone LC-MS/MS-specific cutoffs for the saline infusion test. <i>European Journal of Endocrinology</i> , 2020, 183, 191-201.	1.9	8

#	ARTICLE	IF	CITATIONS
73	Fibroblast Growth Factor 23-Producing Phosphaturic Mesenchymal Tumor with Extraordinary Morphology Causing Oncogenic Osteomalacia. <i>Medicina (Lithuania)</i> , 2020, 56, 34.	0.8	4
74	Treatment of Unilateral PA by Adrenalectomy: Potential Reasons for Incomplete Biochemical Cure. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2019, 127, 100-108.	0.6	15
75	Driver mutations in USP8 wild-type Cushing's disease. <i>Neuro-Oncology</i> , 2019, 21, 1273-1283.	0.6	65
76	Adrenal Insufficiency After Unilateral Adrenalectomy in Primary Aldosteronism: Long-Term Outcome and Clinical Impact. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 5658-5664.	1.8	37
77	Synergistic Highly Potent Targeted Drug Combinations in Different Pheochromocytoma Models Including Human Tumor Cultures. <i>Endocrinology</i> , 2019, 160, 2600-2617.	1.4	24
78	Plasma Steroid Profiles in Subclinical Compared With Overt Adrenal Cushing Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 4331-4340.	1.8	35
79	Clinical Outcomes of 1625 Patients With Primary Aldosteronism Subtyped With Adrenal Vein Sampling. <i>Hypertension</i> , 2019, 74, 800-808.	1.3	97
80	Steroid Profiling and Immunohistochemistry for Subtyping and Outcome Prediction in Primary Aldosteronism—a Review. <i>Current Hypertension Reports</i> , 2019, 21, 77.	1.5	17
81	Primary Aldosteronism. <i>Hypertension</i> , 2019, 74, 809-816.	1.3	27
82	Treatment of Primary Aldosteronism With mTORC1 Inhibitors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 4703-4714.	1.8	7
83	Primary aldosteronism long-term outcome: Medical versus surgical therapy. <i>Current Opinion in Endocrine and Metabolic Research</i> , 2019, 8, 132-138.	0.6	4
84	Therapeutic options after surgical failure in Cushing's disease: A critical review. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2019, 33, 101270.	2.2	20
85	Impaired Glucose Metabolism in Primary Aldosteronism Is Associated With Cortisol Cosecretion. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 3192-3202.	1.8	72
86	Long-Term Outcome of Primary Bilateral Macronodular Adrenocortical Hyperplasia After Unilateral Adrenalectomy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 2985-2993.	1.8	49
87	Tumor-Directed Therapeutic Targets in Cushing Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 925-933.	1.8	24
88	Circulating miRNA Expression Profiling in Primary Aldosteronism. <i>Frontiers in Endocrinology</i> , 2019, 10, 739.	1.5	21
89	Toward a Diagnostic Score in Cushing's Syndrome. <i>Frontiers in Endocrinology</i> , 2019, 10, 766.	1.5	46
90	Sarcopenia — Endocrinological and Neurological Aspects. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2019, 6, 8-22.	0.6	23

#	ARTICLE	IF	CITATIONS
91	Proteomic Landscape of Aldosterone-Producing Adenoma. <i>Hypertension</i> , 2019, 73, 469-480.	1.3	19
92	Classification of microadenomas in patients with primary aldosteronism by steroid profiling. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2019, 189, 274-282.	1.2	28
93	In situ metabolomics of aldosterone-producing adenomas. <i>JCI Insight</i> , 2019, 4, .	2.3	27
94	Safety of medical adjustment and confirmatory testing in the diagnostic work-up of primary aldosteronism. <i>European Journal of Endocrinology</i> , 2019, 181, 421-428.	1.9	11
95	Metabolic impact of pheochromocytoma/paraganglioma: targeted metabolomics in patients before and after tumor removal. <i>European Journal of Endocrinology</i> , 2019, 181, 647-657.	1.9	19
96	Timeline of Advances in Genetics of Primary Aldosteronism. <i>Experientia Supplementum (2012)</i> , 2019, 111, 213-243.	0.5	3
97	MANAGEMENT OF ENDOCRINE DISEASE: Diagnosis and management of primary aldosteronism: the Endocrine Society guideline 2016 revisited. <i>European Journal of Endocrinology</i> , 2018, 179, R19-R29.	1.9	89
98	Worse Health-Related Quality of Life at long-term follow-up in patients with Cushing's disease than patients with cortisol producing adenoma. Data from the <sc>ERCUSYN</sc>. <i>Clinical Endocrinology</i> , 2018, 88, 787-798.	1.2	40
99	Primary aldosteronism: key characteristics at diagnosis: a trend toward milder forms. <i>European Journal of Endocrinology</i> , 2018, 178, 605-611.	1.9	26
100	Anxiety, Depression, and Impaired Quality of Life in Primary Aldosteronism: Why We Shouldn't Ignore It!. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 1-4.	1.8	39
101	Targeting CXCR4 (CXC Chemokine Receptor Type 4) for Molecular Imaging of Aldosterone-Producing Adenoma. <i>Hypertension</i> , 2018, 71, 317-325.	1.3	77
102	Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. <i>European Journal of Endocrinology</i> , 2018, 178, 265-276.	1.9	196
103	Advanced neuroendocrine tumours of the small intestine and pancreas: clinical developments, controversies, and future strategies. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 404-415.	5.5	56
104	Adrenal Surgery for Cushing's Syndrome. <i>Endocrinology and Metabolism Clinics of North America</i> , 2018, 47, 385-394.	1.2	19
105	Genetics of Cushing's disease. <i>Clinical Endocrinology</i> , 2018, 88, 3-12.	1.2	27
106	DIAGNOSIS OF ENDOCRINE DISEASE: 18-Oxocortisol and 18-hydroxycortisol: is there clinical utility of these steroids?. <i>European Journal of Endocrinology</i> , 2018, 178, R1-R9.	1.9	39
107	Plasma Steroid Metabolome Profiling for Diagnosis and Subtyping Patients with Cushing Syndrome. <i>Clinical Chemistry</i> , 2018, 64, 586-596.	1.5	70
108	Cortisol Excess in Patients With Primary Aldosteronism Impacts Left Ventricular Hypertrophy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 4543-4552.	1.8	47

#	ARTICLE	IF	CITATIONS
109	The <i>USP8</i> mutational status may predict long-term remission in patients with Cushing's disease. <i>Clinical Endocrinology</i> , 2018, 89, 454-458.	1.2	56
110	Immunohistopathology and Steroid Profiles Associated With Biochemical Outcomes After Adrenalectomy for Unilateral Primary Aldosteronism. <i>Hypertension</i> , 2018, 72, 650-657.	1.3	51
111	Computed Tomography and Adrenal Venous Sampling in the Diagnosis of Unilateral Primary Aldosteronism. <i>Hypertension</i> , 2018, 72, 641-649.	1.3	94
112	Pathogenesis of Cushing Disease: An Update on the Genetics of Corticotropinomas. <i>Endocrine Practice</i> , 2018, 24, 907-914.	1.1	13
113	Somatic <i>USP8</i> mutations are frequent events in corticotroph tumor progression causing Nelson's tumor. <i>European Journal of Endocrinology</i> , 2018, 178, 57-63.	1.9	37
114	Reference intervals for plasma concentrations of adrenal steroids measured by LC-MS/MS: Impact of gender, age, oral contraceptives, body mass index and blood pressure status. <i>Clinica Chimica Acta</i> , 2017, 470, 115-124.	0.5	116
115	Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 689-699.	5.5	595
116	Cortisol-related metabolic alterations assessed by mass spectrometry assay in patients with Cushing's syndrome. <i>European Journal of Endocrinology</i> , 2017, 177, 227-237.	1.9	23
117	Persistence of myopathy in Cushing's syndrome: evaluation of the German Cushing's Registry. <i>European Journal of Endocrinology</i> , 2017, 176, 737-746.	1.9	57
118	Diagnostic tests for Cushing's syndrome differ from published guidelines: data from ERCUSYN. <i>European Journal of Endocrinology</i> , 2017, 176, 613-624.	1.9	42
119	Old and New Concepts in the Molecular Pathogenesis of Primary Aldosteronism. <i>Hypertension</i> , 2017, 70, 875-881.	1.3	35
120	Expression and mutational status of <i>USP8</i> in tumors causing ectopic ACTH secretion syndrome. <i>Endocrine-Related Cancer</i> , 2017, 24, L73-L77.	1.6	14
121	Cushing's syndrome: a model for sarcopenic obesity. <i>Endocrine</i> , 2017, 57, 481-485.	1.1	26
122	Disordered <i>CYP11B2</i> Expression in Primary Aldosteronism. <i>Hormone and Metabolic Research</i> , 2017, 49, 957-962.	0.7	31
123	The impact of Cushing's syndrome - mild cortisol excess in primary aldosteronism drives diabetes risk. <i>Journal of Hypertension</i> , 2017, 35, 2548.	0.3	18
124	Steroid metabolome analysis reveals prevalent glucocorticoid excess in primary aldosteronism. <i>JCI Insight</i> , 2017, 2, .	2.3	187
125	Genetic Landscape of Sporadic Unilateral Adrenocortical Adenomas Without <i>PRKACA</i> p.Leu206Arg Mutation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 3526-3538.	1.8	65
126	<i>PRKACA</i> Somatic Mutations Are Rare Findings in Aldosterone-Producing Adenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 3010-3017.	1.8	43

#	ARTICLE	IF	CITATIONS
127	Mass Spectrometry-Based Adrenal and Peripheral Venous Steroid Profiling for Subtyping Primary Aldosteronism. <i>Clinical Chemistry</i> , 2016, 62, 514-524.	1.5	123
128	Genotype-Specific Steroid Profiles Associated With Aldosterone-Producing Adenomas. <i>Hypertension</i> , 2016, 67, 139-145.	1.3	127
129	The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 1889-1916.	1.8	1,921
130	Landscape of somatic mutations in sporadic GH-secreting pituitary adenomas. <i>European Journal of Endocrinology</i> , 2016, 174, 363-372.	1.9	100
131	Clinical Management and Outcomes of Adrenal Hemorrhage Following Adrenal Vein Sampling in Primary Aldosteronism. <i>Hypertension</i> , 2016, 67, 146-152.	1.3	63
132	Increased prevalence of diabetes mellitus and the metabolic syndrome in patients with primary aldosteronism of the German Conn's Registry. <i>European Journal of Endocrinology</i> , 2015, 173, 665-675.	1.9	115
133	Cost-Effectiveness of Screening for Primary Aldosteronism and Subtype Diagnosis in the Resistant Hypertensive Patients. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015, 8, 621-630.	0.9	45
134	Genetic and Potential Autoimmune Triggers of Primary Aldosteronism. <i>Hypertension</i> , 2015, 66, 248-253.	1.3	10
135	Time to Recovery of Adrenal Function After Curative Surgery for Cushing's Syndrome Depends on Etiology. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 1300-1308.	1.8	65
136	THERAPY OF ENDOCRINE DISEASE: Outcomes in patients with Cushing's disease undergoing transsphenoidal surgery: systematic review assessing criteria used to define remission and recurrence. <i>European Journal of Endocrinology</i> , 2015, 172, R227-R239.	1.9	114
137	Post-saline infusion test aldosterone levels indicate severity and outcome in primary aldosteronism. <i>European Journal of Endocrinology</i> , 2015, 172, 443-450.	1.9	26
138	The Gene of the Ubiquitin-Specific Protease 8 Is Frequently Mutated in Adenomas Causing Cushing's Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, E997-E1004.	1.8	163
139	Decoding the genetic basis of Cushing's disease: USP8 in the spotlight. <i>European Journal of Endocrinology</i> , 2015, 173, M73-M83.	1.9	46
140	Subclinical hypercortisolism: a state, a syndrome, or a disease?. <i>European Journal of Endocrinology</i> , 2015, 173, M61-M71.	1.9	104
141	Coexisting Prolactinoma and Primary Aldosteronism: Is There a Pathophysiological Link?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, E1262-E1269.	1.8	4
142	A critical reappraisal of bilateral adrenalectomy for ACTH-dependent Cushing's syndrome. <i>European Journal of Endocrinology</i> , 2015, 173, M23-M32.	1.9	74
143	Mutations in the deubiquitinase gene USP8 cause Cushing's disease. <i>Nature Genetics</i> , 2015, 47, 31-38.	9.4	450
144	Adrenal vein sampling in primary aldosteronism: towards a standardised protocol. <i>Lancet Diabetes and Endocrinology</i> , 2015, 3, 296-303.	5.5	134

#	ARTICLE	IF	CITATIONS
145	Genetic Spectrum and Clinical Correlates of Somatic Mutations in Aldosterone-Producing Adenoma. <i>Hypertension</i> , 2014, 64, 354-361.	1.3	248
146	Age Below 40 or a Recently Proposed Clinical Prediction Score Cannot Bypass Adrenal Venous Sampling in Primary Aldosteronism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E1035-E1039.	1.8	95
147	Gender differences in anxiety and depressive symptoms in patients with primary hyperaldosteronism: A cross-sectional study. <i>World Journal of Biological Psychiatry</i> , 2014, 15, 26-35.	1.3	62
148	Outcome of Adrenal Vein Sampling Performed During Concurrent Mineralocorticoid Receptor Antagonist Therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 4397-4402.	1.8	58
149	Favorable long-term outcomes of bilateral adrenalectomy in Cushing's disease. <i>European Journal of Endocrinology</i> , 2014, 171, 209-215.	1.9	83
150	Somatic <i>ATP1A1</i> , <i>ATP2B3</i> , and <i>KCNJ5</i> Mutations in Aldosterone-Producing Adenomas. <i>Hypertension</i> , 2014, 63, 188-195.	1.3	151
151	Linear and Volumetric Evaluation of the Adrenal Gland—MDCT-Based Measurements of the Adrenals. <i>Academic Radiology</i> , 2014, 21, 1465-1474.	1.3	41
152	Adrenal Function After Adrenalectomy for Subclinical Hypercortisolism and Cushing's Syndrome: A Systematic Review of the Literature. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 2637-2645.	1.8	99
153	Outcome of Bilateral Adrenalectomy in Cushing's Syndrome: A Systematic Review. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 3939-3948.	1.8	163
154	Somatic mutations in <i>ATP1A1</i> and <i>ATP2B3</i> lead to aldosterone-producing adenomas and secondary hypertension. <i>Nature Genetics</i> , 2013, 45, 440-444.	9.4	460
155	Lack of influence of somatic mutations on steroid gradients during adrenal vein sampling in aldosterone-producing adenoma patients. <i>European Journal of Endocrinology</i> , 2013, 169, 657-663.	1.9	22
156	Aldosterone Excess Impairs First Phase Insulin Secretion in Primary Aldosteronism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 2513-2520.	1.8	80
157	Effectiveness of eplerenone or spironolactone treatment in preserving renal function in primary aldosteronism. <i>European Journal of Endocrinology</i> , 2013, 168, 75-81.	1.9	58
158	Frequency and causes of adrenal crises over lifetime in patients with 21-hydroxylase deficiency. <i>European Journal of Endocrinology</i> , 2012, 167, 35-42.	1.9	111
159	Observational Study Mortality in Treated Primary Aldosteronism. <i>Hypertension</i> , 2012, 60, 618-624.	1.3	235
160	Quality of life in patients with primary aldosteronism: Gender differences in untreated and long-term treated patients and associations with treatment and aldosterone. <i>Journal of Psychiatric Research</i> , 2012, 46, 1650-1654.	1.5	47
161	The Adrenal Vein Sampling International Study (AVIS) for Identifying the Major Subtypes of Primary Aldosteronism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 1606-1614.	1.8	310
162	Prevalence, Clinical, and Molecular Correlates of <i>KCNJ5</i> Mutations in Primary Aldosteronism. <i>Hypertension</i> , 2012, 59, 592-598.	1.3	246

#	ARTICLE	IF	CITATIONS
163	Adrenal vein sampling using rapid cortisol assays in primary aldosteronism is useful in centers with low success rates. <i>European Journal of Endocrinology</i> , 2011, 165, 301-306.	1.9	93
164	Automated Chemiluminescence-Immunoassay for Aldosterone during Dynamic Testing: Comparison to Radioimmunoassays with and without Extraction Steps. <i>Clinical Chemistry</i> , 2006, 52, 1749-1755.	1.5	136
165	Dehydroepiandrosterone Supplementation in Healthy Men with an Age-Related Decline of Dehydroepiandrosterone Secretion. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 4686-4692.	1.8	123
166	Dehydroepiandrosterone Supplementation in Healthy Men with an Age-Related Decline of Dehydroepiandrosterone Secretion. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 4686-4692.	1.8	42
167	Neuroendocrine Dysfunction in African Trypanosomiasis: The Role of Cytokines. <i>Annals of the New York Academy of Sciences</i> , 1998, 840, 809-821.	1.8	46
168	Expression of adrenocorticotrophic hormone receptor mRNA in human adrenocortical neoplasms: correlation with P450 _{scc} expression. <i>Clinical Endocrinology</i> , 1997, 46, 619-626.	1.2	65
169	Thyroid dysfunction in African trypanosomiasis: a possible role for inflammatory cytokines. <i>Clinical Endocrinology</i> , 1993, 39, 455-461.	1.2	21